The QIV was associated with reduced risks of a body temperature above 39C and lower respiratory tract illness , as compared with the control vaccine , in the per-protocol cohort ( relative risk , 0.29 [ 95 % CI , 0.16 to 0.56 ] and 0.20 [ 95 % CI , 0.04 to 0.92 ] , respectively ) .